Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and ...

Novo Nordisk slumped after a pill from rival Eli Lilly helped patients shed weight and control blood sugar about as well as ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

With President Trump's on-off tariffs causing huge uncertainty in recent weeks, some value stocks have been getting even ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Several hundred units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the Food and Drug Administration.

Novo Nordisk has awarded a 50 million kroner ($7.6M) grant to the University of Copenhagen to develop less processed ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...

The India launch of Eli Lilly’s popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...